We had observed previously that the TR agonist GC-1 strongly reduced hepatic steatosis in western diet fed LDLR-/- mice (S1 Fig) To further study the relationship between TR activation and fatty liver, we treated ob/ob mice, which develop severe hepatic steatosis, with either GC-1 or the related agonist KB2115. The gene discussed is LDLR; the disease is fatty liver disease.